Protocols
SOTIO-BOXR1030 Phase I/II OPEN TO ACCRUAL *
A First-in-Human, Phase 1-2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors